Allergan

Uro Pipeline: UTI vaccine receives fast track designation from FDAOther pipeline developments include an agent to control pain in IC/BPS patients, an antibody to treat prostate and bladder cancer, an injectable OAB treatment, and more.
Reviewing anterior segment ARVO 2017 postersSo much basic science research is presented at this meeting, and most of it will be years before it makes its way to clinical trials. Let’s concentrate on research that might be of use to us in the exam room very soon.
Epicutaneous immunotherapy may transform allergy treatment
Epicutaneous immunotherapy may transform allergy treatmentAs an allergy sufferer myself, I tend to pore over the journals and literature to learn what new exciting technologies may be on the horizon. When I came across epicutaneous immunotherapy (EPIT), my mind went in a multitude of different directions about the endless possibilities for both systemic and ocular allergy management.
Glaucoma, dry eye drugs center of pharmaceutical opportunitiesThe pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.
Growing number of devices set to transform glaucoma treatmentMinimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.
Evolution in glaucoma surgery mounting with MIGS proceduresAn expanding armamentarium of minimally invasive and micro-invasive glaucoma surgery procedures is transforming glaucoma management.
First patients enrolled in dry eye device studyPatient recruitment has started in a randomised clinical trial testing an experimental device (Lamelleye, known also as CXB/1-14) for the treatment of dry eye disease (DED).
Phase 3 trials for acne treatment show promising resultsThe tetracycline-derived antibiotic sarecycline from Allergan plc and Paratek Pharmaceuticals Inc. for the treatment of moderate-to-severe acne has been found effective and safe, according to the results of two phase 3 trials.
Intense pulsed light bridges eye care and aestheticsWhat is this age-defying modern technology that a young, nonmedical professional is applying to her face? It is a YAG laser combined with an intense pulse light (IPL).
Aflibercept rivals laser for diabetic retinopathyIntravitreal aflibercept worked better than panretinal photocoagulation (PRP) for proliferative diabetic retinopathy (PDR) in a new head-to-head trial, according to researchers.